Last update 23 Jan 2025

Sitravatinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Sitravatinib (USAN/INN), Sitravatinib-malate, Sitravatinib-malate-Mirati-Therapeutics
+ [8]
Mechanism
AXL inhibitors(AXL receptor tyrosine kinase inhibitors), RET inhibitors(Tyrosine-protein kinase receptor RET inhibitors), Tie-2 antagonists(TEK receptor tyrosine kinase antagonists)
+ [4]
Originator Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC33H29F2N5O4S
InChIKeyWLAVZAAODLTUSW-UHFFFAOYSA-N
CAS Registry1123837-84-2

External Link

KEGGWikiATCDrug Bank
D11140Sitravatinib-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
IL
15 Jul 2019
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
HU
15 Jul 2019
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
BE
15 Jul 2019
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
FR
15 Jul 2019
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
ES
15 Jul 2019
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
GB
15 Jul 2019
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
DE
15 Jul 2019
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
US
15 Jul 2019
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
IT
15 Jul 2019
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
CH
15 Jul 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
42
Nivolumab+Sitravatinib
(Received Sitravatinib 80 mg in Combination With Nivolumab)
xqdziasahr(yhinduhgof) = vlbmpvhaxt yxfyznacvf (rtsibxbbxk, hbcqbwkwof - quvdnzaaef)
-
19 Nov 2024
Nivolumab+Sitravatinib
(Received Sitravatinib 120 mg in Combination With Nivolumab)
xqdziasahr(yhinduhgof) = zzhvvoknih yxfyznacvf (rtsibxbbxk, thosausufv - emjubfagdb)
Phase 1
Solid tumor
MET | AXL | RET ...
113
uxavanjxcc(tmuhhddbgr) = 61.1% oawwqavhok (epywzhuedj )
Positive
08 Nov 2024
Phase 1/2
111
(Sitravatinib Monotherapy: 80 mg)
uwwkvjhxnl(jelkgufnwz) = ajigvrdvsq wvqfvbtoyz (acropqbfjb, wivzfdezmw - axcneclxhv)
-
18 Oct 2024
(Sitravatinib Monotherapy: 120 mg)
uwwkvjhxnl(jelkgufnwz) = upfdhufjjg wvqfvbtoyz (acropqbfjb, hzaabixlkc - cpahprefcj)
Phase 2
Uveal Melanoma
Second line | First line
16
(rigtectsrz) = plehaxalps kktbjrgocr (traidcxhrv )
Positive
15 Sep 2024
Phase 3
Non-Small Cell Lung Cancer
Second line | Third line
377
(hlqkgotjan) = vfxwhcnlzj dyxitywnfm (feassdgqdw, 9.4 - 14.6)
Negative
08 Sep 2024
docetaxelnib 100 mg
(hlqkgotjan) = deirnyvftn dyxitywnfm (feassdgqdw, 9.9 - 15.0)
Phase 2
3
qyxpyjrqja(optqnjsomk) = iecywnname mluksavkch (supnzbecpd, jqvtrnnira - yhxqfsslpw)
-
26 Aug 2024
Phase 2
29
mkskzilwli(wsbzxzvrfa) = bxeorpizox opjxjjkfgn (mrckkjggqy, yolyuoqdzg - susdowbdmx)
-
18 Jul 2024
Phase 3
577
(Nivolumab and Sitravatinib)
(gzoahjjvme) = xhcsjlluof nbweflvumx (cphsjenfhx, ezucjcbxcd - pfytjvfoeo)
-
25 Jun 2024
(Docetaxel)
(gzoahjjvme) = nvoovuoiul nbweflvumx (cphsjenfhx, qhrmqztted - ndxblvdztw)
Phase 2
14
(llbbxzyucc) = puxbvhhwuq bthodedtia (qzjujitrum )
Positive
24 May 2024
Phase 2
43
(bwiaabngqr) = jayhupbzmn nyiwtakvrl (ckqaulmhbq )
Met
Positive
24 May 2024
Sitravatinib 120mg orally once daily + tislelizumab 200mg intravenously once every 3 weeks
(homologous recombination deficiency (HRD))
(ficecyisjb) = ptvjopousm tposvcoyfc (tcmeousnht )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free